Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | MYC | P01106 | 1/20 | 0.41 |
| ▸ | USP8 | P40818 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.38 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.37 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.37 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TYMS | P04818 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7222595 | 0.78 | ADORA2A (0.50) | DPP4ALDH1A1MEN1POLBKMT2A | |
| SCHEMBL30423822 | 0.77 | CA1 (0.44) | CA1CA2CA9CA7MYC | |
| SCHEMBL5155563 | 0.75 | CA1 (0.43) | CA1CA2CA9CA7MYC | |
| SCHEMBL3375220 | 0.74 | CA2 (0.46) | CA1CA2CA9CA7ALDH1A1 | |
| SCHEMBL4850007 | 0.74 | MAOA (0.56) | CA1CA2CA9CA7ALDH1A1 | |
| SCHEMBL7887080 | 0.74 | TDP2 (0.56) | ALDH1A1POLBNPC1CYP3A4TSHR | |
| SCHEMBL9781818 | 0.74 | CES1 (0.38) | DAOGRIA1CACNG8ALDH1A1NPC1 | |
| SCHEMBL10621855 | 0.74 | HDAC4 (0.47) | ALDH1A1MEN1KMT2AMAPK1SMN1; SMN2 | |
| SCHEMBL3642843 | 0.72 | PGAM1 (0.40) | MYCALDH1A1MEN1KMT2ACYP3A4 | |
| SCHEMBL2763213 | 0.72 | KEAP1 (0.56) | FGFR1ALDH1A1NPC1TSHRRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1358163-A1 | MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2003-11-05 | — | — | EP | claimed |
| WO-2002059095-A1 | MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-08-01 | — | — | WO | claimed |
| EP-1804093-B1 | INFRARED ABSORBING FILTER | OSAKA GAS CO LTD (JP) | 2016-12-07 | — | — | EP | disclosed |
| US-8470844-B2 | Imidazoacridinone derivative compounds and methods for their use | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2013-06-25 | — | — | US | disclosed |
| US-7772356-B2 | Infrared absorption filter | OSAKA GAS CO., LTD. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-20100137351-A1 | Imidazoacridinone derivative compounds and methods for their use | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2010-06-03 | — | — | US | disclosed |
| US-20070293606-A1 | Infrared Absorption Filter | OSAKA GAS CO., LTD. (JP) | 2007-12-20 | — | — | US | disclosed |
| EP-1804093-A1 | INFRARED ABSORBING FILTER | OSAKA GAS CO., LTD. (JP) | 2007-07-04 | — | — | EP | disclosed |
| EP-1146037-B1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE AMINO ALCOHOLS | NIPPON SODA CO (JP) | 2006-06-21 | — | — | EP | disclosed |
| WO-2006002022-A2 | COMPOSITIONS AND METHODS USEFUL FOR THE TREATMENT OF HYPERGLYCEMIA | IMMUSOL INCORPORATED (US) | 2006-01-05 | — | — | WO | disclosed |
| EP-1126833-A4 | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | TREGA BIOSCIENCES INC (US) | 2004-09-08 | — | — | EP | disclosed |
| US-6008373-A | FLUORESCENT LABELING COMPLEXES CONTAIN REACTIVE GROUPS FOR LABELING OF FUNCTIONAL GROUP OR TARGET COMPOUNDS SUCH AS ANTIBODIES, DNA SEQUENCES, ENZYMES, AND PROTEIN MATERIAL | CARNEGIE MELLON UNIVERSITY (US) | 1999-12-28 | — | — | US | disclosed |
| US-5925527-A | SCREENING NEW PHARMACEUTICALS | TREGA BIOSCIENCES, INC. (US) | 1999-07-20 | — | — | US | disclosed |
| EP-0923734-A1 | QUINOLINE DERIVATIVES AND QUINOLINE COMBINATORIAL LIBRARIES | Trega Biosciences, Inc. (US) | 1999-06-23 | — | — | EP | disclosed |
| US-5840500-A | OPIOD RECEPTORS AS ANALGESICS AND CENTRALLY ACTING PAIN KILLERS | TREGA BIOSCIENCES, INC. (US) | 1998-11-24 | — | — | US | disclosed |
| WO-1998034111-A1 | TRICYCLIC TETRAHYDROQUINOLINE DERIVATIVES AND TRICYCLIC TETRAHYDROQUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 1998-08-06 | — | — | WO | disclosed |
| WO-1998034115-A1 | 4-SUBSTITUTED-QUINOLINE DERIVATIVES AND 4-SUBSTITUTE-QUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 1998-08-06 | — | — | WO | disclosed |
| WO-1998002741-A9 | QUINOLINE DERIVATIVES AND QUINOLINE COMBINATORIAL LIBRARIES | — | 1998-05-22 | — | — | WO | disclosed |
| WO-1998002741-A1 | QUINOLINE DERIVATIVES AND QUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 1998-01-22 | — | — | WO | disclosed |
| US-4950770-A | Psoralens aminomethylation | ELDER PHARMACEUTICALS, INC. (US) | 1990-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137351-A1 | Imidazoacridinone derivative compounds and methods for their use | IDH3A, IDH3B, ABL1 | CA1 1027/4885CA2 1534/4885CA9 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.